Related content

Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer

By Sørbye Halfdan   Berglund Åke   Tveit Kjell Magne   Øgreid Dagfinn   Wanderås Eva Hoff   Wentzel-Larsen Tore   Dahl Olav   Glimelius Bengt  

Acta Oncologica, Vol. 46, Iss. 7, 2007-01 ,pp. : 982-988

Informa Healthcare

Access to resources Recommend Favorite

Raltitrexed plus weekly oxaliplatin as first-line chemotherapy in metastatic colorectal cancer: A multicenter non-randomized phase II study

By Santini Daniele   Massacesi Cristian   D’Angelillo Rolando   Marcucci Fabiana   Campisi Costantino   Vincenzi Bruno   Pilone Alberta   Bianco Vincenzo   Bonsignori Maurizio   Tonini Giuseppe  

Medical Oncology, Vol. 21, Iss. 1, 2004-03 ,pp. : 59-66

Humana Press, Inc

Access to resources Recommend Favorite

Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype

By            

International Journal of Oncology, Vol. 44, Iss. 1, 2014-01 ,pp. : 17-26

Spandidos Publications

Access to resources Recommend Favorite

First-line single-agent chemotherapy for patients with recurrent or metastatic gastric cancer with poor performance status

By                

Experimental and Therapeutic Medicine, Vol. 4, Iss. 4, 2012-01 ,pp. : 562-568

Spandidos Publications

Access to resources Recommend Favorite

First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients

By  

Oncology Letters, Vol. 9, Iss. 2, 2015-01 ,pp. : 987-993

Spandidos Publications

Access to resources Recommend Favorite